EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Prospective randomized multicenter trial on the outpatient use of subcutaneous interleukin 2 and interferon alpha-2b in high risk melanoma patients



Prospective randomized multicenter trial on the outpatient use of subcutaneous interleukin 2 and interferon alpha-2b in high risk melanoma patients



Melanoma Research 7(SUPPL 1): S115-S116




(PDF emailed within 1 workday: $29.90)

Accession: 032996866

Download citation: RISBibTeXText



Related references

A prospective randomized multi-centre trial for the treatment of primary high-risk melanoma using sc interleukin-2 and interferon alpha. Melanoma Research 5(6): 445, 1995

Multicenter phase III randomized trial of polychemotherapy versus the same chemotherapy plus subcutaneous interleukin-2 and interferon-alpha-2b in metastatic melanoma. EJC Supplements 1(5): S252, September, 2003

Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. Journal of Clinical Oncology 20(6): 1600-1607, 2002

Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. Journal of Interferon & Cytokine Research 21(4): 257-263, 2001

Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma: Less efficacy compared with intravenous interleukin-2 and interferon alpha: Results of a multicenter phase II trial from the Groupe Francais d'lmmunotherapie. Cancer 95(11): 2324-2330, December 1, 2002

Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie. Cancer 95(11): 2324-2330, 2002

A prospective randomised multi-centre trial for the treatment of primary high-risk melanoma using sc interleukin-2 and interferon-alpha. Melanoma Research 7(2): 163-164, 1997

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Annals of Oncology 17(4): 571-577, 2006

Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial. Journal of Clinical Oncology 20(6): 1600-1607, 2002

A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma. Annals of Oncology 13(12): 1919-1924, 2002

Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. Journal of Clinical Oncology 21(15): 2883-2888, 2003

Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Cancer 85(5): 1060-1066, 1999

Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. Journal of Clinical Oncology 27(21): 3496-3502, 2009

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. Journal of Clinical Oncology 11(9): 1809-1816, 1993

A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Research 19(1): 42-49, 2009